Search

Your search keyword '"Di Giorgio, Mary Ann"' showing total 12 results
Start Over Author "Di Giorgio, Mary Ann"
12 results on '"Di Giorgio, Mary Ann"'

1. Effectiveness, safety, and tolerability of delayed dexamethasone, rituximab, and cyclophosphamide as first-line treatment in patients with Waldenström macroglobulinemia: data from the Sicilian Myeloma Network.

Author

Del Fabro, Vittorio, Markovic, Uros, Frazzetto, Sara, Sciortino, Roberta, Bellofiore, Claudia, Di Giorgio, Mary Ann, Leotta, Valerio, Bulla, Anna, Curto Pelle, Angelo, Elia, Federica, Mannina, Donato, Consoli, Ugo, Mineo, Giuseppe, Giallongo, Cesarina, Romano, Alessandra, Di Raimondo, Francesco, and Conticello, Concetta

Published
2024
Full Text
View/download PDF

2. The role of ponatinib in adult BCR-ABL1 positive acute lymphoblastic leukemia after allogeneic transplantation: a real-life retrospective multicenter study

Author

Leotta, Salvatore, Markovic, Uros, Pirosa, Maria Cristina, Stella, Stefania, Tringali, Stefania, Martino, Massimo, Specchia, Giorgina, Carluccio, Paola, Risitano, Antonio M., Grimaldi, Francesco, Vigna, Ernesto, Palmieri, Fausto, Palmieri, Raffaele, Annunziata, Mario, Pisapia, Giovanni, Palazzo, Giulia, Milone, Giulio Antonio, Pelle, Angelo Curto, Scalise, Luca, Di Giorgio, Mary Ann, Bulla, Anna, Leotta, Valerio, Di Raimondo, Francesco, and Milone, Giuseppe

Published
2021
Full Text
View/download PDF

3. Lenalidomide plus Dexamethasone Combination as First-Line Oral Therapy of Multiple Myeloma Patients: A Unicentric Real-Life Study

Author

Del Fabro, Vittorio, primary, Di Giorgio, Mary Ann, additional, Leotta, Valerio, additional, Duminuco, Andrea, additional, Bellofiore, Claudia, additional, Markovic, Uros, additional, Romano, Alessandra, additional, Bulla, Anna, additional, Curto Pelle, Angelo, additional, Elia, Federica, additional, Di Raimondo, Francesco, additional, and Conticello, Concetta, additional

Published
2023
Full Text
View/download PDF

6. Isavuconazole Prophylaxis during Early Phases of Allogeneic HSC Transplantation Is Not Associated to an Increase Need of Cyclosporin-a Dose Modification

Author

Cupri, Alessandra, primary, Leotta, Salvatore, additional, Markovic, Uros, additional, Camuglia, Maria Grazia, additional, Milone, Giulio Antonio, additional, Curto Pelle, Angelo, additional, Leotta, Valerio, additional, Di Giorgio, Mary Ann, additional, Bulla, Anna, additional, Anna Lia, Di Marco, additional, Moschetti, Gaetano, additional, and Milone, Giuseppe, additional

Published
2019
Full Text
View/download PDF

7. Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

Author

Parisi, Marina Silvia, primary, Leotta, Salvatore, additional, Romano, Alessandra, additional, Del Fabro, Vittorio, additional, Martino, Enrica Antonia, additional, Calafiore, Valeria, additional, Giubbolini, Rachele, additional, Markovic, Uros, additional, Leotta, Valerio, additional, Di Giorgio, Mary Ann, additional, Tibullo, Daniele, additional, Di Raimondo, Francesco, additional, and Conticello, Concetta, additional

Published
2019
Full Text
View/download PDF

8. Pomalidomide-Responsive Extramedullary Myeloma Relapsed after Allogeneic Hematopoietic Transplant and Refractory to Multiple Lines of Chemotherapy

Author

Leotta, Salvatore, primary, Pirosa, Maria Cristina, additional, Markovic, Uros, additional, Scalise, Luca, additional, Bulla, Anna, additional, Sapienza, Giuseppe, additional, Di Giorgio, Mary Ann, additional, Martino, Enrica Antonia, additional, Curto Pelle, Angelo, additional, Leotta, Valerio, additional, Milone, Giulio, additional, Cupri, Alessandra, additional, Vaddinelli, Doriana, additional, Villari, Loredana, additional, Conticello, Concetta, additional, and Milone, Giuseppe, additional

Published
2019
Full Text
View/download PDF

9. The Combined Evaluation of Neutrophil, T-Lymphocyte and Monocyte Counts Provides New Prognostic Information in CLL Patients

Author

Chiarenza, Annalisa, primary, Parrinello, Nunziatina Laura, additional, Triolo, Anna Maria, additional, Rizzo, Giuseppina, additional, Romano, Alessandra, additional, Maugeri, Cinzia, additional, Caruso, Laura Anastasia, additional, Motta, Giovanna, additional, Figuera, Amalia, additional, Curto Pelle, Angelo, additional, Leotta, Valerio, additional, Di Giorgio, Mary Ann, additional, La Cava, Piera, additional, Giallongo, Cesarina, additional, Tibullo, Daniele, additional, and Di Raimondo, Francesco, additional

Published
2016
Full Text
View/download PDF

10. Luspatercept in the Treatment of Beta Thalassemia in Italy: Lights and Shadows in Clinical Practice

Author

Gianesin, Barbara, Rosso, Rosamaria, Lisi, Roberto, Zappu, Antonietta, Motta, Irene, Longo, Filomena, Pinto, Valeria, Sanna, Paola Maria Grazia, De Franceschi, Lucia, Ruffo, Giovan Battista, DI Maggio, Rosario, Bulla, Anna, Di Giorgio, Mary Ann, Denotti, Anna Rita, Panzieri, Daniele Lello, Culcasi, Martina, Quintino, Sabrina, Marchisio, Andrea, Mazzi, Filippo, Miciotto, Francesca, Barone, Rita, Di Raimondo, Francesco, Ferraresi, Marta, Marchetti, Beatrice, and Origa, Raffaella

Abstract

Luspatercept has been demonstrated to reduce the need for blood transfusion with manageable side effects in clinical trials, thus receiving the approval for the treatment of anemia associated with transfusion dependent beta thalassemia in adults. However, very little data on its safety and efficacy in real life have been hitherto published. Special warnings and precautions for use refer to the possibility of occurrence of thromboembolic events, extramedullary hemopoiesis masses and increased blood pressure. Ten Italian Specialized Centres for the treatment of Hemoglobinopathies, with the patronage of the “Società Italiana Talassemie ed Emoglobinopatie” (SITE), evaluated the effects of luspatercept in terms of safety and blood transfusion reduction in 116 patients (Table 1) who received the first dose of the drug after its marketing. The median duration of treatment was 158 days (min-max: 15-442). β globin genotype was β 0/β 0in 42 subjects (36.2%), β 0/ β +in 33 (28.4%), β +/ β +in 23 (19.8%), β 0/β wtplus α gene triplication in 4 (3.4%) and unknown in 14 (12%). Sixty-four patients (55.2%) were splenectomized. At the time of data collection, 32 patients (27.6%) had already discontinued the drug. Discontinuation had occurred after a median time of 132 days of treatment (min-max: 15-338) due to insufficient efficacy in the judgement of the physician (10) or patient (3), side effects attributed to luspatercept (16) that were detrimental to the continuation of therapy in the judgement of the physician (6) or patient (10), pregnancy (1) and other causes (2).

Published
2023
Full Text
View/download PDF

11. Neutrophil to T-Lymphocyte Ratio (NLR) and Neutrophil to Monocyte Ratio (NMR) Are Promising Biomarkers in Chronic Lymphocytic Leukemia Prognostic Assessment

Author

Chiarenza, Annalisa, Di Raimondo, Francesco, Parrinello, Nunziatina Laura, Triolo, Anna, Rizzo, Giuseppina, Curto Pelle, Angelo, Maugeri, Cinzia, Caruso, Anastasia Laura, Motta, Giovanna, Figuera, Amalia, Romano, Alessandra, Leotta, Valerio, Di Giorgio, Mary Ann, Giallongo, Cesarina, and Tibullo, Daniele

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results